[go: up one dir, main page]

WO2007112675A8 - Protéine de fusion du récepteur du vegf et son utilisation - Google Patents

Protéine de fusion du récepteur du vegf et son utilisation Download PDF

Info

Publication number
WO2007112675A8
WO2007112675A8 PCT/CN2007/001021 CN2007001021W WO2007112675A8 WO 2007112675 A8 WO2007112675 A8 WO 2007112675A8 CN 2007001021 W CN2007001021 W CN 2007001021W WO 2007112675 A8 WO2007112675 A8 WO 2007112675A8
Authority
WO
WIPO (PCT)
Prior art keywords
fusion protein
vegf receptor
receptor fusion
flt
domains
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2007/001021
Other languages
English (en)
French (fr)
Other versions
WO2007112675A1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chengdu Kanghong Biotechnologies Co Ltd
Original Assignee
Chengdu Kanghong Biotechnologies Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu Kanghong Biotechnologies Co Ltd filed Critical Chengdu Kanghong Biotechnologies Co Ltd
Priority to EP07720595A priority Critical patent/EP2000483A4/en
Priority to JP2009501824A priority patent/JP2009531036A/ja
Priority to CA002647142A priority patent/CA2647142A1/en
Priority to BRPI0710223-2A priority patent/BRPI0710223A2/pt
Priority to AU2007234272A priority patent/AU2007234272A1/en
Publication of WO2007112675A1 publication Critical patent/WO2007112675A1/zh
Priority to US12/241,017 priority patent/US20090264358A1/en
Anticipated expiration legal-status Critical
Priority to US12/457,478 priority patent/US8216575B2/en
Publication of WO2007112675A8 publication Critical patent/WO2007112675A8/zh
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PCT/CN2007/001021 2006-03-31 2007-03-29 Protéine de fusion du récepteur du vegf et son utilisation Ceased WO2007112675A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP07720595A EP2000483A4 (en) 2006-03-31 2007-03-29 VEGF RECEPTOR FUSION PROTEIN AND APPLICATION THEREOF
JP2009501824A JP2009531036A (ja) 2006-03-31 2007-03-29 Ｖｅｇｆ受容体融合タンパク質およびそれらの使用
CA002647142A CA2647142A1 (en) 2006-03-31 2007-03-29 Vegf receptor fusion protein and use thereof
BRPI0710223-2A BRPI0710223A2 (pt) 2006-03-31 2007-03-29 proteìnas de fusão de receptor de vegf e seu uso
AU2007234272A AU2007234272A1 (en) 2006-03-31 2007-03-29 VEGF receptor fusion protein and use thereof
US12/241,017 US20090264358A1 (en) 2006-03-31 2008-09-29 Vegf receptor fusion proteins, their pharmaceutical compositions and therapeutic applications for the eye diseases
US12/457,478 US8216575B2 (en) 2006-03-31 2009-06-11 Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200610066257.2 2006-03-31
CNB2006100662572A CN100502945C (zh) 2006-03-31 2006-03-31 Vegf受体融合蛋白在治疗眼睛疾病中的应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/241,017 Continuation US20090264358A1 (en) 2006-03-31 2008-09-29 Vegf receptor fusion proteins, their pharmaceutical compositions and therapeutic applications for the eye diseases

Publications (2)

Publication Number Publication Date
WO2007112675A1 WO2007112675A1 (fr) 2007-10-11
WO2007112675A8 true WO2007112675A8 (fr) 2009-07-09

Family

ID=37736587

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2007/001021 Ceased WO2007112675A1 (fr) 2006-03-31 2007-03-29 Protéine de fusion du récepteur du vegf et son utilisation

Country Status (10)

Country Link
US (1) US20090264358A1 (zh)
EP (1) EP2000483A4 (zh)
JP (1) JP2009531036A (zh)
KR (1) KR20090010030A (zh)
CN (1) CN100502945C (zh)
AU (1) AU2007234272A1 (zh)
BR (1) BRPI0710223A2 (zh)
CA (1) CA2647142A1 (zh)
RU (1) RU2008136655A (zh)
WO (1) WO2007112675A1 (zh)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2633574T3 (es) 2005-03-25 2017-09-22 Regeneron Pharmaceuticals, Inc. Formulaciones de antagonistas de VEGF
SI2944306T1 (sl) 2006-06-16 2021-04-30 Regeneron Pharmaceuticals, Inc. Formulacije antagonista VEGF, primerne za intravitrealno dajanje
CN101279092B (zh) * 2007-04-02 2010-10-27 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备治疗与血管生成有关的疾病中的应用
CN101721699B (zh) * 2008-10-13 2012-11-07 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备治疗伴随vegf升高的炎症反应的药物中的应用
KR101248912B1 (ko) * 2009-12-31 2013-03-29 한양대학교 산학협력단 항혈관신생 활성을 가지는 재조합 아데노바이러스
CN102233132B (zh) * 2010-04-28 2013-10-23 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备抑制眼表新生血管生长的药物中的应用
CN102380096B (zh) * 2010-08-31 2014-04-30 成都康弘生物科技有限公司 一种含有抑制血管增生的融合蛋白的药物组合物及用途
CN103816115B (zh) * 2010-08-31 2017-06-27 成都康弘生物科技有限公司 一种含有抑制血管增生的融合蛋白的药物组合物及用途
MX385629B (es) 2011-01-13 2025-03-18 Regeneron Pharma Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos.
KR102049990B1 (ko) 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP6631865B2 (ja) * 2014-08-11 2020-01-15 日本化薬株式会社 ＴＧＦβ阻害機能を持つキメラタンパク質
HRP20220066T1 (hr) 2014-12-11 2022-04-15 Bayer Healthcare Llc Liječenje makularne degeneracije povezane sa starenjem s malom aktivnom koroidnom neovaskularizacijskom lezijom
WO2017046140A1 (en) 2015-09-18 2017-03-23 Bayer Pharma Aktiengesellschaft Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
HUE059827T2 (hu) 2017-11-30 2023-01-28 Regeneron Pharma VEGF-antagonista alkalmazása angiogén szembetegségek kezelésére
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
NZ770284A (en) 2018-05-10 2025-11-28 Regeneron Pharma High concentration vegf receptor fusion protein containing formulations
CN111328336B (zh) * 2018-12-07 2024-01-30 荣昌生物制药(烟台)股份有限公司 一种双功能血管生成抑制剂及其用途
US20230057380A1 (en) * 2019-11-26 2023-02-23 University Of Massachusetts Recombinant adeno-associated virus for delivery of kh902 (conbercept) and uses thereof
JP2022548197A (ja) 2019-12-06 2022-11-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｖｅｇｆタンパク質組成物及びその製造方法
CN115803009A (zh) 2020-05-08 2023-03-14 瑞泽恩制药公司 用于治疗眼病和癌症的vegf阱和微阱及方法
EP4185318B1 (en) 2021-05-17 2025-09-03 Regeneron Pharmaceuticals, Inc. Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
CN119365206A (zh) 2022-03-15 2025-01-24 瑞泽恩制药公司 用于治疗血管生成性眼病的延长的高剂量vegf拮抗剂方案
US20240024420A1 (en) 2022-03-15 2024-01-25 Regeneron Pharmaceuticals, Inc. Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders
JP2025529465A (ja) 2022-09-16 2025-09-04 チールー ファーマシューティカル カンパニー、リミテッド 安定な高濃度自己緩衝医薬組成物
JP2025003405A (ja) 2023-06-23 2025-01-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 眼内血管新生性疾患の治療のための、ｖｅｇｆアンタゴニストの延長された高用量レジメン
WO2025140553A1 (zh) * 2023-12-27 2025-07-03 成都康弘生物科技有限公司 一种含有抗vegf的融合蛋白的药物组合物
WO2025217334A1 (en) 2024-04-09 2025-10-16 Regeneron Pharmaceuticals, Inc. Low concentration vegf receptor fusion protein containing formulations
CN118108862B (zh) * 2024-04-29 2024-08-09 上海鼎新基因科技有限公司 抗血管新生的融合蛋白及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
JP4723140B2 (ja) * 1999-06-08 2011-07-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 改善された薬物動態特性を有する改変キメラポリペプチド
BRPI0414604A (pt) * 2003-09-23 2006-11-07 Novartis Ag combinações de um inibiddor do receptor de vegf com outros agentes terapêuticos
CN1304427C (zh) * 2004-06-08 2007-03-14 成都康弘生物科技有限公司 抑制血管新生的融合蛋白质及其用途
DK1767546T3 (da) * 2004-06-08 2012-04-23 Chengdu Kanghong Biotechnologies Co Ltd Angiogenese-inhiberende kimært protein og dets anvendelse

Also Published As

Publication number Publication date
BRPI0710223A2 (pt) 2011-08-02
US20090264358A1 (en) 2009-10-22
CA2647142A1 (en) 2007-10-11
WO2007112675A1 (fr) 2007-10-11
RU2008136655A (ru) 2010-05-10
EP2000483A9 (en) 2009-03-18
JP2009531036A (ja) 2009-09-03
EP2000483A4 (en) 2009-10-28
CN1915427A (zh) 2007-02-21
AU2007234272A1 (en) 2007-10-11
EP2000483A2 (en) 2008-12-10
CN100502945C (zh) 2009-06-24
KR20090010030A (ko) 2009-01-28

Similar Documents

Publication Publication Date Title
WO2007112675A8 (fr) Protéine de fusion du récepteur du vegf et son utilisation
TW200640443A (en) Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
WO2007111864A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
MX2009004714A (es) Derivados de pirazol fusionado 3-aminocarbonilo sustituidos como moduladores de proteina cinasa.
WO2008008286A3 (en) Substituted pyrazoles as ghrelin receptor antagonists
ATE417928T1 (de) Vegf-rezeptorchimären zur behandlung von augenkrankheiten, welche durch vaskuläre permeabilität charakterisiert sind.
WO2009097017A3 (en) Antibodies and fc fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof
TN2009000105A1 (en) Compounds and compositions as protein kinase inhibitors
WO2009120717A3 (en) Pyrido [3, 4-b] indoles and methods of use
NO20072802L (no) Nye antranilamidpyridinureaer som vaskulaerendotelvekstfaktor (VEGF) -reseptorkinaseinhibitorer
WO2007047207A3 (en) 5-lipoxygenase-activating protein (flap) inhibitors
WO2008063888A3 (en) Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2006044614A3 (en) Anti-angiogenic peptides and methods of use thereof
EP3444242A3 (en) Novel benzopyran kinase modulators
WO2010008831A3 (en) Compounds and methods for modulating g protein-coupled receptors
WO2007056228A3 (en) 5-lipoxygenase-activating protein (flap) inhibitors
WO2008073441A3 (en) Compositions and methods for treating pathologic angiogenesis and vascular permeability
WO2007101864A3 (en) Compounds that modulate ppar activity, their preparation and use
WO2007131219A3 (en) Cannabinoid receptor antagonists/inverse agonists
WO2008054748A3 (en) Indazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
MY147642A (en) Novel anthranilamide pyridinureas as vascular endothelial growth factor (vegf) receptor kinase inhibitors
WO2006065722A3 (en) Compositions and methods for pulmonary conditions
WO2009045700A3 (en) 5-lipoxygenase-activating protein (flap) inhibitors
EP2374455A3 (en) Modulators of muscarinic receptors
WO2004085617A3 (en) Timp3 as vegf inhibitor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07720595

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 7954/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2007234272

Country of ref document: AU

Ref document number: 2647142

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009501824

Country of ref document: JP

Ref document number: 2007720595

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007234272

Country of ref document: AU

Date of ref document: 20070329

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020087025464

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2008136655

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0710223

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080929